NABOTA
NABOTA by Daewoong Pharmaceutical is the only Korean botulinum toxin with triple certification: US FDA (as Jeuveau, 2019), European EMA, and Taiwan TFDA. Its proprietary HI-PURE technology delivers 98%+ purity at 900kDa — the same molecular weight as Allergan Botox — allowing direct 1:1 dosage equivalence. Duration 4–6 months.
30 分鐘
免費諮詢 · 專屬顧問 · 無額外費用
療程效果
- 全球唯一通過美國 FDA、歐洲 EMA、台灣 TFDA 三重認證的韓國肉毒
- HI-PURE™ 專利純化技術，純度達 98% 以上
- 與保妥適相同 900kDa 分子量，劑量 1:1 等量替換，醫師操作最便利
- 臨床試驗確認副作用低，長期施打抗體產生風險小
- 美國以品牌名 Jeuveau 上市，歐美市場接受度最高的韓國肉毒
- 效果穩定，2 至 3 天起效，維持 4 至 6 個月
適合對象
- 重視國際認證、追求最高規格安全保障的韓國肉毒使用者
- 曾在台灣或歐美使用保妥適、希望以相同劑量轉換韓國品牌者
- 眉間紋、抬頭紋、魚尾紋等動態紋路困擾者
- 咀嚼肌縮小（國字臉）瘦臉塑型需求者
- 小腿腓腸肌（蘿蔔腿）雕塑需求者
- 多汗症（腋下、手腳）改善需求者
注意事項
Avoid lying down, strenuous activity, alcohol, and high-temperature environments for at least one week post-injection. Contraindicated in pregnancy, breastfeeding, myasthenia gravis, and neuromuscular disorders. Stop blood thinners 2 weeks prior. Disclose any prior botulinum toxin allergic reactions.
常見問題
NABOTA 適合哪些人？+
NABOTA 療程需要多久？+
NABOTA 有哪些注意事項？+
如何透過 BeaVoy 預約 NABOTA？+
你可能也感興趣
GOURI
GOURI is the world's first fully liquid PCL (polycaprolactone) injectable collagen stimulator, developed by Korean company Dexlevo using patented CESABP technology. Injected at just 10 facial points in under 20 minutes, it spreads evenly to stimulate fibroblasts across the full face and neck, producing gradual collagen regeneration that lasts 6–12 months with minimal downtime.
了解更多XEOMIN
XEOMIN (incobotulinumtoxinA) by Germany's Merz is the world's only "naked" botulinum toxin, stripped of all complexing proteins via proprietary XTRACT dual-purification technology. This minimizes antibody formation risk, making it the preferred choice for patients with prior botulinum toxin resistance. Onset is 2–4 days, with effects lasting 4–6 months.
了解更多NEURAMIS
NEURAMIS is a Korean HA filler by Medytox using proprietary SHAPE cross-linking technology with ultra-low residual BDDE levels, certified by both the US FDA and European EDQM. Results last 8–18 months with a clinical two-year response rate of 84%.
了解更多